spacer
home > pmps > winter 2002 > formulation integrated device systems for novel enhanced performance products
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Formulation Integrated Device Systems for Novel Enhanced Performance Products

The aim of developing formulation integrated device systems (FIDS) is to achieve enhanced performance from drugs, using technology that is aimed at solving specific biopharmaceutical, therapeutic, clinical or production problems. These patent-protected high performance systems are designed to provide better treatment outcomes and greater satisfaction for patients, whilst enabling new product development applications and enhanced Ôlife cycle managementŐ opportunities for pharmaceutical companies.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Professor John N Staniforth, Chief Scientific Officer at Vectura Ltd
Professor John N Staniforth PhD MRPharmS FZS CChem FRSC Churchill Fellow, is Chief Scientific Officer of Vectura, a pharmaceutical company specialising in novel pulmonary, oral and dermal technology and new product developments, based in the UK.

John has authored over 200 scientific publications in the area of pharmaceutical technology and is an Honorary Professor of the University of Bath. He is a Non-Executive Director of Penwest Pharmaceuticals Co Inc, New York, and a Founding Director of the drug delivery company, Phoqus Pharmaceuticals Ltd, UK.

spacer
Professor John N Staniforth
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Signant Health Appoints Lawrence Miller as Chief Technology Officer

LONDON & PHILADELPHIA – June 13, 2019: Signant Health, formerly CRF Bracket, has appointed Lawrence Miller as Chief Technology Officer. Signant unites electronic Clinical Outcomes Assessment (eCOA), eConsent, Patient Engagement, Interactive Response Technology (IRT), Clinical Supply Management and Endpoint Quality into the industry’s most comprehensive patient-centric suite of technology solutions and services. An accomplished innovator, Miller brings unique vision and expertise to a Signant team already committed to advancing clinical research with its next-generation technology portfolio.
More info >>

White Papers

The Impact of Components on Drug Quality and Risk Mitigation

West Pharmaceutical Services, Inc.

Expectations for quality by regulatory agencies are increasing at a very fast pace, especially for prefilled drug delivery formats, thanks to increased focus on reducing risk to patient safety. The trend has resulted in delays for new drug applications, more recalls of marketed products and even drug shortages if the container system and drug contents are suspect for quality issues. The pharmaceutical market is now requiring manufacturers of containers and components to meet new expectations with a quality culture and very high product reliability. The need to bridge the gap and provide superior quality products has been a driver for manufacturing technology investments, more robust control strategies and the introduction of next generation elastomer components.
More info >>

 
Industry Events

Nordic Life Science Days 10/12 September 2019

10-12 September 2019, Malmo Sweden

Nordic Life Science Days is the largest Nordic partnering conference for the global Life Science industry. Bringing together the best talents in Life Science, offering amazing networking and partnering opportunities, providing inputs and content on the most recent trends. Nordic Life Science Days attracts leading decision makers from the Life Science sector, not only from biotech, pharma and medtech but also from finances, research, policy and regulatory authorities.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement